![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MCL1 |
Gene summary for MCL1 |
![]() |
Gene information | Species | Human | Gene symbol | MCL1 | Gene ID | 4170 |
Gene name | MCL1 apoptosis regulator, BCL2 family member | |
Gene Alias | BCL2L3 | |
Cytomap | 1q21.2 | |
Gene Type | protein-coding | GO ID | GO:0001709 | UniProtAcc | A0A087WT64 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4170 | MCL1 | GSM4909286 | Human | Breast | IDC | 6.39e-05 | -2.39e-01 | 0.1081 |
4170 | MCL1 | GSM4909293 | Human | Breast | IDC | 5.77e-09 | 3.84e-01 | 0.1581 |
4170 | MCL1 | GSM4909294 | Human | Breast | IDC | 2.74e-05 | -4.17e-01 | 0.2022 |
4170 | MCL1 | GSM4909296 | Human | Breast | IDC | 8.41e-08 | -2.10e-01 | 0.1524 |
4170 | MCL1 | GSM4909297 | Human | Breast | IDC | 6.26e-09 | -1.87e-01 | 0.1517 |
4170 | MCL1 | GSM4909299 | Human | Breast | IDC | 2.79e-07 | 4.20e-01 | 0.035 |
4170 | MCL1 | GSM4909301 | Human | Breast | IDC | 8.48e-88 | 1.06e+00 | 0.1577 |
4170 | MCL1 | GSM4909308 | Human | Breast | IDC | 9.89e-03 | 2.93e-01 | 0.158 |
4170 | MCL1 | GSM4909311 | Human | Breast | IDC | 8.66e-27 | -3.07e-01 | 0.1534 |
4170 | MCL1 | GSM4909312 | Human | Breast | IDC | 8.38e-04 | 8.22e-02 | 0.1552 |
4170 | MCL1 | GSM4909319 | Human | Breast | IDC | 1.12e-35 | -6.05e-01 | 0.1563 |
4170 | MCL1 | GSM4909320 | Human | Breast | IDC | 2.46e-06 | -5.35e-01 | 0.1575 |
4170 | MCL1 | GSM4909321 | Human | Breast | IDC | 4.44e-08 | 2.00e-02 | 0.1559 |
4170 | MCL1 | brca2 | Human | Breast | Precancer | 6.51e-03 | -8.41e-02 | -0.024 |
4170 | MCL1 | brca3 | Human | Breast | Precancer | 2.99e-04 | -1.06e-02 | -0.0263 |
4170 | MCL1 | brca10 | Human | Breast | Precancer | 9.33e-04 | -3.85e-01 | -0.0029 |
4170 | MCL1 | NCCBC14 | Human | Breast | DCIS | 8.16e-07 | -3.13e-01 | 0.2021 |
4170 | MCL1 | NCCBC5 | Human | Breast | DCIS | 5.78e-08 | -3.78e-01 | 0.2046 |
4170 | MCL1 | P1 | Human | Breast | IDC | 1.48e-12 | -1.66e-01 | 0.1527 |
4170 | MCL1 | DCIS2 | Human | Breast | DCIS | 1.88e-46 | 4.59e-01 | 0.0085 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00621979 | Breast | Precancer | cellular response to chemical stress | 51/1080 | 337/18723 | 2.40e-10 | 2.34e-08 | 51 |
GO:20012349 | Breast | Precancer | negative regulation of apoptotic signaling pathway | 39/1080 | 224/18723 | 5.35e-10 | 4.77e-08 | 39 |
GO:20012439 | Breast | Precancer | negative regulation of intrinsic apoptotic signaling pathway | 23/1080 | 98/18723 | 5.82e-09 | 4.45e-07 | 23 |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:20012445 | Breast | Precancer | positive regulation of intrinsic apoptotic signaling pathway | 17/1080 | 58/18723 | 1.59e-08 | 1.12e-06 | 17 |
GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
GO:00345999 | Breast | Precancer | cellular response to oxidative stress | 42/1080 | 288/18723 | 2.78e-08 | 1.79e-06 | 42 |
GO:20012356 | Breast | Precancer | positive regulation of apoptotic signaling pathway | 24/1080 | 126/18723 | 1.98e-07 | 1.01e-05 | 24 |
GO:19021758 | Breast | Precancer | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 11/1080 | 29/18723 | 2.95e-07 | 1.44e-05 | 11 |
GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
GO:00435237 | Breast | Precancer | regulation of neuron apoptotic process | 31/1080 | 212/18723 | 1.69e-06 | 6.08e-05 | 31 |
GO:19032019 | Breast | Precancer | regulation of oxidative stress-induced cell death | 16/1080 | 74/18723 | 3.80e-06 | 1.20e-04 | 16 |
GO:20012369 | Breast | Precancer | regulation of extrinsic apoptotic signaling pathway | 24/1080 | 151/18723 | 5.78e-06 | 1.70e-04 | 24 |
GO:00086318 | Breast | Precancer | intrinsic apoptotic signaling pathway in response to oxidative stress | 12/1080 | 45/18723 | 6.23e-06 | 1.76e-04 | 12 |
GO:00313309 | Breast | Precancer | negative regulation of cellular catabolic process | 34/1080 | 262/18723 | 8.16e-06 | 2.20e-04 | 34 |
GO:00971919 | Breast | Precancer | extrinsic apoptotic signaling pathway | 30/1080 | 219/18723 | 9.42e-06 | 2.50e-04 | 30 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0415133 | Oral cavity | EOLP | PI3K-Akt signaling pathway | 73/1218 | 354/8465 | 7.03e-04 | 2.69e-03 | 1.59e-03 | 73 |
hsa046301 | Oral cavity | EOLP | JAK-STAT signaling pathway | 35/1218 | 166/8465 | 1.15e-02 | 3.07e-02 | 1.81e-02 | 35 |
hsa041515 | Prostate | BPH | PI3K-Akt signaling pathway | 104/1718 | 354/8465 | 2.07e-05 | 1.55e-04 | 9.61e-05 | 104 |
hsa0421016 | Prostate | BPH | Apoptosis | 46/1718 | 136/8465 | 1.41e-04 | 8.31e-04 | 5.14e-04 | 46 |
hsa0415112 | Prostate | BPH | PI3K-Akt signaling pathway | 104/1718 | 354/8465 | 2.07e-05 | 1.55e-04 | 9.61e-05 | 104 |
hsa0421017 | Prostate | BPH | Apoptosis | 46/1718 | 136/8465 | 1.41e-04 | 8.31e-04 | 5.14e-04 | 46 |
hsa0415122 | Prostate | Tumor | PI3K-Akt signaling pathway | 105/1791 | 354/8465 | 7.42e-05 | 5.30e-04 | 3.28e-04 | 105 |
hsa0421025 | Prostate | Tumor | Apoptosis | 48/1791 | 136/8465 | 9.03e-05 | 6.10e-04 | 3.78e-04 | 48 |
hsa0415132 | Prostate | Tumor | PI3K-Akt signaling pathway | 105/1791 | 354/8465 | 7.42e-05 | 5.30e-04 | 3.28e-04 | 105 |
hsa0421035 | Prostate | Tumor | Apoptosis | 48/1791 | 136/8465 | 9.03e-05 | 6.10e-04 | 3.78e-04 | 48 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MCL1 | SNV | Missense_Mutation | c.724G>A | p.Asp242Asn | p.D242N | Q07820 | protein_coding | tolerated(0.11) | benign(0.268) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
MCL1 | insertion | In_Frame_Ins | novel | c.734_735insCAAACTGTTGGT | p.Ser245_Leu246insLysLeuLeuVal | p.S245_L246insKLLV | Q07820 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
MCL1 | insertion | Frame_Shift_Ins | novel | c.732_733insGCTTCTCTTC | p.Ser245AlafsTer35 | p.S245Afs*35 | Q07820 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
MCL1 | SNV | Missense_Mutation | c.485N>G | p.Ser162Trp | p.S162W | Q07820 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
MCL1 | SNV | Missense_Mutation | novel | c.823G>A | p.Ala275Thr | p.A275T | Q07820 | protein_coding | deleterious(0.02) | possibly_damaging(0.546) | TCGA-AA-3976-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR |
MCL1 | SNV | Missense_Mutation | novel | c.543T>G | p.Ile181Met | p.I181M | Q07820 | protein_coding | tolerated(0.1) | benign(0.231) | TCGA-AA-3976-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR |
MCL1 | SNV | Missense_Mutation | novel | c.74G>A | p.Ser25Asn | p.S25N | Q07820 | protein_coding | tolerated_low_confidence(0.12) | benign(0.023) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MCL1 | SNV | Missense_Mutation | novel | c.844N>C | p.Asn282His | p.N282H | Q07820 | protein_coding | deleterious(0.04) | probably_damaging(0.956) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
MCL1 | SNV | Missense_Mutation | novel | c.361T>A | p.Ser121Thr | p.S121T | Q07820 | protein_coding | tolerated(0.07) | benign(0.202) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
MCL1 | SNV | Missense_Mutation | novel | c.679N>A | p.Ala227Thr | p.A227T | Q07820 | protein_coding | deleterious(0.04) | possibly_damaging(0.628) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | PMID27744724-Compound-13 | |||
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | PROCHLORPERAZINE | PROCHLORPERAZINE | ||
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | SULFURETIN | SULFURETIN | ||
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | PMID27744724-Compound-22 | |||
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | APOMORPHINE HYDROCHLORIDE HEMIHYDRATE | APOMORPHINE HYDROCHLORIDE HEMIHYDRATE | ||
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | CB7969312 | CHEMBL599255 | ||
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | SJ000036432 | CHEMBL591135 | ||
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | AMENTOFLAVONE | AMENTOFLAVONE | ||
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | antagonist | 252166530 | VENETOCLAX | |
4170 | MCL1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | LOMOFUNGIN | LOMOFUNGIN |
Page: 1 2 3 4 5 6 7 8 |